Nothing Special   »   [go: up one dir, main page]

EA201991894A1 - ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ - Google Patents

ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ

Info

Publication number
EA201991894A1
EA201991894A1 EA201991894A EA201991894A EA201991894A1 EA 201991894 A1 EA201991894 A1 EA 201991894A1 EA 201991894 A EA201991894 A EA 201991894A EA 201991894 A EA201991894 A EA 201991894A EA 201991894 A1 EA201991894 A1 EA 201991894A1
Authority
EA
Eurasian Patent Office
Prior art keywords
piperidine
substituted
compounds
formula
mnk inhibitors
Prior art date
Application number
EA201991894A
Other languages
English (en)
Inventor
Джастин Т. Эрнст
Пол А. Шпренгелер
Зигфрид Х Райх
Сэмьюэл Сперри
Original Assignee
Эффектор Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эффектор Терапьютикс, Инк. filed Critical Эффектор Терапьютикс, Инк.
Publication of EA201991894A1 publication Critical patent/EA201991894A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Настоящее изобретение относится к соединениям в соответствии с формулой (I)или к стереоизомеру, таутомеру или фармацевтически приемлемой соли такого соединения, где X, X, R, R, Rи n имеют значения, определенные в настоящей заявке. Также описаны фармацевтически приемлемые композиции соединений формулы (I), a также способы применения соединений формулы (I) и фармацевтически приемлемых композиций соединений формулы (I) в качестве ингибиторов Mnk, а также терапевтических средств для лечения заболеваний, таких как рак.
EA201991894A 2017-02-14 2018-02-13 ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ EA201991894A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762458671P 2017-02-14 2017-02-14
PCT/US2018/018022 WO2018152117A1 (en) 2017-02-14 2018-02-13 Piperidine-substituted mnk inhibitors and methods related thereto

Publications (1)

Publication Number Publication Date
EA201991894A1 true EA201991894A1 (ru) 2020-02-05

Family

ID=63106539

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991894A EA201991894A1 (ru) 2017-02-14 2018-02-13 ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ

Country Status (21)

Country Link
US (3) US20180228803A1 (ru)
EP (1) EP3582776B1 (ru)
JP (2) JP2020507588A (ru)
KR (1) KR20190117013A (ru)
CN (1) CN110719781A (ru)
AU (2) AU2018220840A1 (ru)
BR (1) BR112019016707A2 (ru)
CA (1) CA3053493A1 (ru)
CL (1) CL2019002297A1 (ru)
CO (1) CO2019009423A2 (ru)
DK (1) DK3582776T3 (ru)
EA (1) EA201991894A1 (ru)
ES (1) ES2969988T3 (ru)
FI (1) FI3582776T3 (ru)
IL (1) IL268619B (ru)
MX (1) MX2019009653A (ru)
PE (1) PE20191349A1 (ru)
PH (1) PH12019550140A1 (ru)
SG (1) SG11201907356SA (ru)
TW (1) TWI762579B (ru)
WO (1) WO2018152117A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020507588A (ja) 2017-02-14 2020-03-12 イーフェクター セラピューティクス， インコーポレイテッド ピぺリジン置換ＭｎＫ阻害剤およびそれに関連する方法
US11130757B2 (en) 2018-10-24 2021-09-28 Effector Therapeutics Inc. Crystalline forms of MNK inhibitors
CN111484494B (zh) * 2019-01-29 2022-09-13 诺沃斯达药业(上海)有限公司 抑制mnk1和mnk2的多环化合物
PT4063364T (pt) 2019-11-18 2024-10-30 Jumbo Drug Bank Co Ltd Compostos de pirrolotriazina que atuam como inibidor de mnk
EP4200296A1 (en) * 2020-08-20 2023-06-28 Hepagene Therapeutics (HK) Limited Mnk inhibitors
JP2024516885A (ja) 2021-05-08 2024-04-17 成都嘉葆薬銀医薬科技有限公司 ピロロトリアジン系化合物の塩形、その結晶形及びその製造方法
CN114736205B (zh) * 2022-03-31 2023-03-03 武汉九州钰民医药科技有限公司 化合物Tomivosertib的制备方法
CN114853756B (zh) * 2022-03-31 2023-03-28 武汉九州钰民医药科技有限公司 化合物Tomivosertib的制备工艺
WO2024017229A1 (zh) * 2022-07-19 2024-01-25 成都嘉葆药银医药科技有限公司 一种吡咯并三嗪类化合物在制备抗肿瘤药物中的应用
CN116425750A (zh) * 2023-02-10 2023-07-14 诺沃斯达药业(上海)有限公司 一种mnk抑制剂化合物的盐、晶体及其制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491144A (en) 1991-05-30 1996-02-13 Ciba-Geigy Corporation Substituted diaminophthalimides and analogues
US7105506B2 (en) 2001-06-05 2006-09-12 Lilly Icos Llc Tetracyclic compounds as PDE5-inhibitors
ES2359233T3 (es) 2001-10-29 2011-05-19 Boehringer Ingelheim International Gmbh Proteínas homólogas de la quinasa mnk implicadas en la regulación de la homeostasis energética y en el metabolismo organular.
US20050012622A1 (en) 2003-05-19 2005-01-20 Sutton William R. Monitoring and control of sleep cycles
TWI301760B (en) 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
US20060281670A1 (en) 2005-06-10 2006-12-14 Wisconsin Alumni Research Foundation (Warf) Compositions and methods for modulating angiogenesis
JP2009509921A (ja) 2005-08-12 2009-03-12 アストラゼネカ アクチボラグ 置換イソインドロン類及び代謝調節型グルタミン酸受容体増強剤としてのその使用
DE602007004618D1 (de) 2006-06-22 2010-03-18 Biovitrum Ab Publ Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
JP5569956B2 (ja) 2007-03-16 2014-08-13 ザ スクリプス リサーチ インスティテュート 接着斑キナーゼのインヒビター
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
EP2219649A2 (en) 2007-11-22 2010-08-25 Boehringer Ingelheim International Gmbh Use of mnk inhibitors for the treatment of alzheimer's disease
JP2009173629A (ja) 2007-12-21 2009-08-06 Banyu Pharmaceut Co Ltd Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体
WO2009112445A1 (en) 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
AU2009286734A1 (en) * 2008-08-26 2010-03-04 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
EP2355819A2 (en) 2008-11-12 2011-08-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating a mnk
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
WO2011017296A1 (en) 2009-08-04 2011-02-10 Schering Corporation 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
US8604217B2 (en) 2009-11-12 2013-12-10 Selvita S.A. Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
WO2011106168A1 (en) 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
NZ608584A (en) 2010-10-01 2015-07-31 Bayer Ip Gmbh Substituted n-(2-arylamino)aryl sulfonamide-containing combinations
EP2646453A1 (en) 2010-11-30 2013-10-09 Gilead Pharmasset LLC Compounds
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
WO2013043192A1 (en) 2011-09-23 2013-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders
PE20141404A1 (es) 2011-12-30 2014-10-28 Hanmi Pharm Ind Co Ltd Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
CA2868966C (en) 2012-03-29 2021-01-26 Francis Xavier Tavares Lactam kinase inhibitors
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
US20150133426A1 (en) 2012-05-21 2015-05-14 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyrimidines
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
EP2917185B1 (en) 2012-11-09 2017-05-10 Evotec International GmbH Sulfoximine substituted quinazolines for pharmaceutical compositions
GB2508652A (en) 2012-12-07 2014-06-11 Agency Science Tech & Res Heterocyclic piperazine derivatives
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
CA2901527A1 (en) 2013-02-20 2014-08-28 Bayer Pharma Aktiengesellschaft Substituted-imidazo[1,2-b]pyridazines as mknk1 inhibitors
TW201605867A (zh) 2013-11-20 2016-02-16 拜耳製藥公司 噻吩并嘧啶
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
AU2015366417A1 (en) 2014-12-19 2017-06-29 Bayer Pharma Aktiengesellschaft Pyrazolopyridinamines as MKNK1 and MKNK2 inhibitors
CN107750167B (zh) 2015-04-20 2021-05-25 效应物治疗公司 用于治疗癌症和感染的免疫检查点调节剂的抑制剂
MX2018005203A (es) 2015-10-29 2018-07-06 Effector Therapeutics Inc Compuestos de pirrolo-, pirazolo-, imidazo-pirimidina y pirrolo-, pirazolo-, imidazo-piridina que inhiben cinasas 1 y 2 de interaccion con proteina cinasas activadas por mitogenos (mnk1 y mnk2).
JP6892444B2 (ja) 2015-10-29 2021-06-23 イーフェクター セラピューティクス， インコーポレイテッド Ｍｎｋ１およびｍｎｋ２のイソインドリン、アザイソインドリン、ジヒドロインデノンならびにジヒドロアザインデノン阻害薬
GB201520499D0 (en) 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
GB201520500D0 (en) 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
WO2017087808A1 (en) 2015-11-20 2017-05-26 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
EP3397774A1 (en) 2015-12-31 2018-11-07 Effector Therapeutics Inc. Mnk biomarkers and uses thereof
AU2017382830A1 (en) * 2016-12-19 2019-06-13 Epizyme, Inc. Amine-substituted heterocyclic compounds as EHMT2 inhibitors and methods of use thereof
JP2020507588A (ja) 2017-02-14 2020-03-12 イーフェクター セラピューティクス， インコーポレイテッド ピぺリジン置換ＭｎＫ阻害剤およびそれに関連する方法
WO2018218038A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
EP3710053A1 (en) 2017-11-16 2020-09-23 Novartis AG Combination therapies
WO2019103926A1 (en) 2017-11-21 2019-05-31 Saint Louis University P38 inhibitors for the treatment of fshd
US11130757B2 (en) 2018-10-24 2021-09-28 Effector Therapeutics Inc. Crystalline forms of MNK inhibitors

Also Published As

Publication number Publication date
DK3582776T3 (da) 2024-01-08
MX2019009653A (es) 2019-12-19
US20220096472A1 (en) 2022-03-31
US11083727B2 (en) 2021-08-10
PE20191349A1 (es) 2019-09-30
WO2018152117A1 (en) 2018-08-23
CL2019002297A1 (es) 2019-11-08
IL268619A (en) 2019-10-31
EP3582776A4 (en) 2020-09-02
EP3582776B1 (en) 2023-11-08
IL268619B (en) 2022-05-01
CO2019009423A2 (es) 2019-09-09
AU2022202864B2 (en) 2024-06-06
JP2022185050A (ja) 2022-12-13
EP3582776A1 (en) 2019-12-25
TWI762579B (zh) 2022-05-01
PH12019550140A1 (en) 2020-06-01
AU2018220840A1 (en) 2019-09-19
AU2022202864A1 (en) 2022-05-19
TW201835076A (zh) 2018-10-01
JP2020507588A (ja) 2020-03-12
US20190275039A1 (en) 2019-09-12
US20180228803A1 (en) 2018-08-16
FI3582776T3 (fi) 2024-01-03
US11878015B2 (en) 2024-01-23
CA3053493A1 (en) 2018-08-23
SG11201907356SA (en) 2019-09-27
BR112019016707A2 (pt) 2020-04-07
CN110719781A (zh) 2020-01-21
ES2969988T3 (es) 2024-05-23
KR20190117013A (ko) 2019-10-15

Similar Documents

Publication Publication Date Title
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201891229A1 (ru) Eif4a-ингибирующие соединения и связанные с ними способы
EA201991399A1 (ru) Аминотриазолопиридиновые соединения и их применение в лечении рака
EA202090530A1 (ru) Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
EA201690752A1 (ru) Ингибиторы g12c kras
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201792214A1 (ru) Соединения замещенного хиназолина
EA201991884A3 (ru) Ингибиторы g12c kras
EA201690094A1 (ru) Ингибиторы syk
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201791955A1 (ru) ИНГИБИТОРЫ TGF-β
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA202193015A1 (ru) Ингибиторы cdk
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA202192905A1 (ru) Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
EA201692557A1 (ru) Хинолизиноновые производные в качестве ингибиторов pi3k
EA202090900A1 (ru) Ингибиторы иммунопротеасом
EA202191548A1 (ru) Ингибиторы плазменного калликреина человека
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
EA202192760A1 (ru) Трициклические соединения